Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Jacinth Joseph, MD, Vanessa Wookey, MD, Brion Randolph, MD, Jason C. Chandler, MD, Dennis Marjoncu, PharmD, BCOP, Kori Holman, PharmD, Deniscer Peeler, LPN, Michelle Armstrong, NP, Yasser Khaled, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143049

Published: 2020

Journal Articles

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Poojitha Valasareddy, MD, Arnel Pallera, MD, Robert Johnson, MD, Deniscer Peeler, LPN, Jason C. Chandler, MD, Joel Gradowski, MD

Blood (2019) 134 (Supplement_1): 5676.

https://doi.org/10.1182/blood-2019-131954

Published: 2019

Journal Articles

Improved Relapse Rate, T Cell Recovery and Engraftment in High Risk Hematological Malignancies with Enhanced Lympho-Depletion Prior to T-Cell Replete Peripheral Blood Haploidentical (HID) Hematopoietic Stem Cell Transplantation (HCT)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Joel Gradowski, MD, Robert Bradley, MD, Jason C. Chandler, MD

Blood (2018) 132 (Supplement 1): 2117.

https://doi.org/10.1182/blood-2018-99-115290

Published: 2018

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Yasser Khaled, MD, Jason C. Chandler, MD, Joshua Boss, RN, OCN, Arnel Pallera, MD, Michael G. Martin, MD, Robert Bradley, MD, Robert Johnson, MD

Blood (2017) 130 (Supplement 1): 1934.

https://doi.org/10.1182/blood.V130.Suppl_1.1934.1934

Published: 2017

Journal Articles

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2017) 130 (Supplement 1): 1551.

https://doi.org/10.1182/blood.V130.Suppl_1.1551.1551

Published: 2017

Journal Articles

A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001

Blood (2016) 128 (22): 1849.

https://doi.org/10.1182/blood.V128.22.1849.1849

Published: 2016

Journal Articles

The Addition of Rituximab to Chemotherapy Decreased Rates of Primary Surgery for Gastric Diffuse Large B-Cell Lymphoma without Increasing Early Mortality

Eric Wiedower, DO, Smith Giri, MBBS, Andrew Fintel, DO, Philip Prouet, MD, Elena Paulus, MD, Jason C. Chandler, MD, Mike G. Martin, MD

Blood (2015) 126 (23): 4475.

https://doi.org/10.1182/blood.V126.23.4475.4475

Published: 2015

Journal Articles

Comorbidities Drive Outcomes for Both Malignancy and Non-Malignancy Associated Hemophagocytic Syndrome

Benny Johnson, DO, Smith Giri, MBBS, Sara E. Nunnery, Eric Wiedower, DO, Omer Jamy, MD, Jason C. Chandler, MD, Mike G. Martin, MD

Blood (2015) 126 (23): 3261.

https://doi.org/10.1182/blood.V126.23.3261.3261

Published: 2015

Journal Articles

Single Cell Network Profiling as a Platform to Reveal Leukemia-Specific Signaling Signatures and Sensitivity to Kinase Inhibitor Therapies

Todd M. Covey, Michael Gulrajani, Heiko Becker, MD, Jason C. Chandler, MD, Sebastian Schwind, MD, Guido Marcucci, MD, Alessandra Cesano, MD

Blood (2010) 116 (21): 2753.

https://doi.org/10.1182/blood.V116.21.2753.2753

Published: 2010

Journal Articles

Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway

Il-Kyoo Park, Anjali Mishra, Jason C. Chandler, Michael A. Caligiuri

Blood (2010) 116 (21): 500.

https://doi.org/10.1182/blood.V116.21.500.500

Published: 2010

Journal Articles

Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia

Blood (2010) 116 (21): 704.

https://doi.org/10.1182/blood.V116.21.704.704

Published: 2010

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Blood (2009) 114 (22): 855.

https://doi.org/10.1182/blood.V114.22.855.855

Published: 2009

NARROW

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

Improved Relapse Rate, T Cell Recovery and Engraftment in High Risk Hematological Malignancies with Enhanced Lympho-Depletion Prior to T-Cell Replete Peripheral Blood Haploidentical (HID) Hematopoietic Stem Cell Transplantation (HCT)

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001

The Addition of Rituximab to Chemotherapy Decreased Rates of Primary Surgery for Gastric Diffuse Large B-Cell Lymphoma without Increasing Early Mortality

Comorbidities Drive Outcomes for Both Malignancy and Non-Malignancy Associated Hemophagocytic Syndrome

Single Cell Network Profiling as a Platform to Reveal Leukemia-Specific Signaling Signatures and Sensitivity to Kinase Inhibitor Therapies

Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway

Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only